DAB: a three-drug combination provides alternative to 5-HT3 receptor drugs.
McDermott
M
M
Oncology Services, United Hospital, St. Paul, MN, USA.
D000970:Antineoplastic Agents / Q000009:adverse effects; D003907:Dexamethasone / Q000008:administration & dosage*; D004155:Diphenhydramine / Q000008:administration & dosage*; D004338:Drug Combinations; D006801:Humans; D008140:Lorazepam / Q000008:administration & dosage*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000970:Antineoplastic Agents; D004338:Drug Combinations; D012702:Serotonin Antagonists; D003907:Dexamethasone; D004155:Diphenhydramine; D008140:Lorazepam